# **Special Issue**

# Marine Compounds and Inflammation II

# Message from the Guest Editors

Marine metabolites own a unique chemical diversity, containing structural requirements that allow binding to specific targets, and cover a wide range of biological properties that are closely related to their pharmacological potential and therapeutic success in the most diverse diseases. The drug discovery process is moving toward a rationalization in which chemistry and pharmacology converge towards targeted approaches, focused on specific diseases and molecular targets. Inflammation is a defensive response of an organism in which harmful factors, such as pathogens, heat, and cancer cells produce tissue damage. It involves a multitude of cell types, chemical mediators, and interactions. An enormous demand exists for new and potent anti-inflammatory drugs because inflammation underlies a multitude of human diseases, including atherosclerosis, inflammatory bowel diseases, diabetes, rheumatoid arthritis, Alzheimer's disease, and, in particular, the start and progression of cancer. As of this Special Issue of Marine Drugs, we invite you to report your findings in the field of marine anti-inflammatory compounds.

## **Guest Editors**

Prof. Dr. Agostino Casapullo

Department of Pharmacy, University of Salerno, via Giovanni Paolo II 132, 84084 Fisciano, Italy

Prof. Dr. Virginia Motilva

Department of Pharmacology, School of Pharmacy, University of Seville, Seville, Spain

### Deadline for manuscript submissions

closed (15 December 2020)



# **Marine Drugs**

an Open Access Journal by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



mdpi.com/si/32201

Marine Drugs Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 marinedrugs@mdpl.com

mdpi.com/journal/marinedrugs





an Open Access Journal by MDPI

Impact Factor 5.4 CiteScore 10.1 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

## **Editor-in-Chief**

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

### **Author Benefits**

# **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

